Analyst Price Targets — VRDN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 3:36 pm | Kelly Shi | Jefferies | $45.00 | $28.80 | StreetInsider | Viridian Therapeutic (VRDN) PT Raised to $45 at Jefferies |
| January 28, 2026 11:41 am | Gavin Clark-Gartner | Evercore ISI | $45.00 | $33.14 | StreetInsider | Viridian Therapeutic (VRDN) PT Raised to $45 at Evercore ISI |
| January 20, 2026 1:20 pm | Gavin Clark-Gartner | Evercore ISI | $44.00 | $32.63 | TheFly | Viridian Therapeutics price target raised to $44 from $42 at Evercore ISI |
| January 7, 2026 1:23 pm | — | UBS | $50.00 | $30.82 | TheFly | Viridian Therapeutics initiated with a Buy at UBS |
| December 3, 2025 11:13 am | — | William Blair | $47.00 | $30.43 | TheFly | Viridian Therapeutics initiated with an Outperform at William Blair |
| November 24, 2025 12:20 pm | — | Truist Financial | $41.00 | $30.34 | TheFly | Viridian Therapeutics initiated with a Buy at Truist |
| November 6, 2025 6:55 pm | — | RBC Capital | $45.00 | $27.50 | TheFly | Viridian Therapeutics price target raised to $45 from $41 at RBC Capital |
| November 6, 2025 2:26 pm | — | Goldman Sachs | $40.00 | $28.11 | TheFly | Viridian Therapeutics price target raised to $40 from $30 at Goldman Sachs |
| November 5, 2025 5:06 pm | Alex Thompson | Stifel Nicolaus | $48.00 | $24.24 | StreetInsider | Viridian Therapeutic (VRDN) PT Raised to $48 at Stifel |
| October 21, 2025 11:51 am | — | Oppenheimer | $36.00 | $24.49 | TheFly | Viridian Therapeutics price target raised to $36 from $32 at Oppenheimer |
Latest News for VRDN
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $0.81 per share a year ago.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. “We enter 2026 with the momentum of our continued execution,” said…
Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating
Campbell and CO Investment Adviser LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 26,315 shares of the company's stock, valued at approximately $568,000. A number of other large investors
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VRDN.
U.S. House Trading
No House trades found for VRDN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.